Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50


JNK1 Deficient Insulin-Producing Cells Are Protected against Interleukin-1β-Induced Apoptosis Associated with Abrogated Myc Expression.

Prause M, Mayer CM, Brorsson C, Frederiksen KS, Billestrup N, Størling J, Mandrup-Poulsen T.

J Diabetes Res. 2016;2016:1312705. doi: 10.1155/2016/1312705. Epub 2016 Jan 10.


MicroRNAs: Novel Players in the Dialogue between Pancreatic Islets and Immune System in Autoimmune Diabetes.

Ventriglia G, Nigi L, Sebastiani G, Dotta F.

Biomed Res Int. 2015;2015:749734. doi: 10.1155/2015/749734. Epub 2015 Aug 3. Review.


θ-Defensin RTD-1 improves insulin action and normalizes plasma glucose and FFA levels in diet-induced obese rats.

Oh YT, Tran D, Buchanan TA, Selsted ME, Youn JH.

Am J Physiol Endocrinol Metab. 2015 Jul 15;309(2):E154-60. doi: 10.1152/ajpendo.00131.2015. Epub 2015 May 19.


Phospho-BAD BH3 mimicry protects β cells and restores functional β cell mass in diabetes.

Ljubicic S, Polak K, Fu A, Wiwczar J, Szlyk B, Chang Y, Alvarez-Perez JC, Bird GH, Walensky LD, Garcia-Ocaña A, Danial NN.

Cell Rep. 2015 Feb 3;10(4):497-504. doi: 10.1016/j.celrep.2014.12.056. Epub 2015 Jan 29.


Altering β-cell number through stable alteration of miR-21 and miR-34a expression.

Backe MB, Novotny GW, Christensen DP, Grunnet LG, Mandrup-Poulsen T.

Islets. 2014;6(1):e27754. doi: 10.4161/isl.27754.


Possible role of interleukin-1β in type 2 diabetes onset and implications for anti-inflammatory therapy strategies.

Zhao G, Dharmadhikari G, Maedler K, Meyer-Hermann M.

PLoS Comput Biol. 2014 Aug 28;10(8):e1003798. doi: 10.1371/journal.pcbi.1003798. eCollection 2014 Aug.


HDAC inhibitor-mediated beta-cell protection against cytokine-induced toxicity is STAT1 Tyr701 phosphorylation independent.

Dahllöf MS, Christensen DP, Harving M, Wagner BK, Mandrup-Poulsen T, Lundh M.

J Interferon Cytokine Res. 2015 Jan;35(1):63-70. doi: 10.1089/jir.2014.0022. Epub 2014 Jul 25.


Stem cell therapy for diabetes mellitus.

Voltarelli JC, Couri CE, Oliveira MC, Moraes DA, Stracieri AB, Pieroni F, Barros GM, Malmegrim KC, Simões BP, Leal AM, Foss MC.

Kidney Int Suppl (2011). 2011 Sep;1(3):94-98. Review.


CTSH regulates β-cell function and disease progression in newly diagnosed type 1 diabetes patients.

Fløyel T, Brorsson C, Nielsen LB, Miani M, Bang-Berthelsen CH, Friedrichsen M, Overgaard AJ, Berchtold LA, Wiberg A, Poulsen P, Hansen L, Rosinger S, Boehm BO, Ram R, Nguyen Q, Mehta M, Morahan G, Concannon P, Bergholdt R, Nielsen JH, Reinheckel T, von Herrath M, Vaag A, Eizirik DL, Mortensen HB, Størling J, Pociot F.

Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):10305-10. doi: 10.1073/pnas.1402571111. Epub 2014 Jun 30.


CEBPA exerts a specific and biologically important proapoptotic role in pancreatic β cells through its downstream network targets.

Barbagallo D, Condorelli AG, Piro S, Parrinello N, Fløyel T, Ragusa M, Rabuazzo AM, Størling J, Purrello F, Di Pietro C, Purrello M.

Mol Biol Cell. 2014 Aug 15;25(16):2333-41. doi: 10.1091/mbc.E14-02-0703. Epub 2014 Jun 18.


Type 2 diabetes, PUFAs, and vitamin D: their relation to inflammation.

Guadarrama-López AL, Valdés-Ramos R, Martínez-Carrillo BE.

J Immunol Res. 2014;2014:860703. doi: 10.1155/2014/860703. Epub 2014 Feb 24. Review.


A synergistic therapeutic scheme for hyperglycemia and nephrotic disorders in diabetes.

He Q, Zhang X, Han B, Xu J, Tang K, Fu Z, Yin H.

Theranostics. 2014 Mar 5;4(5):556-64. doi: 10.7150/thno.7847. eCollection 2014.


Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and β-cell protection.

Christensen DP, Gysemans C, Lundh M, Dahllöf MS, Noesgaard D, Schmidt SF, Mandrup S, Birkbak N, Workman CT, Piemonti L, Blaabjerg L, Monzani V, Fossati G, Mascagni P, Paraskevas S, Aikin RA, Billestrup N, Grunnet LG, Dinarello CA, Mathieu C, Mandrup-Poulsen T.

Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1055-9. doi: 10.1073/pnas.1320850111. Epub 2014 Jan 6.


Diabetes and beta cell function: from mechanisms to evaluation and clinical implications.

Cernea S, Dobreanu M.

Biochem Med (Zagreb). 2013;23(3):266-80. Review.


Small-molecule inhibition of inflammatory β-cell death.

Lundh M, Scully SS, Mandrup-Poulsen T, Wagner BK.

Diabetes Obes Metab. 2013 Sep;15 Suppl 3:176-84. doi: 10.1111/dom.12158. Review.


Interleukin-1 antagonists and other cytokine blockade strategies for type 1 diabetes.

Mandrup-Poulsen T.

Rev Diabet Stud. 2012 Winter;9(4):338-47. doi: 10.1900/RDS.2012.9.338. Epub 2012 Dec 28. Review.


Enhancing pancreatic Beta-cell regeneration in vivo with pioglitazone and alogliptin.

Yin H, Park SY, Wang XJ, Misawa R, Grossman EJ, Tao J, Zhong R, Witkowski P, Bell GI, Chong AS.

PLoS One. 2013 Jun 6;8(6):e65777. doi: 10.1371/journal.pone.0065777. Print 2013.


Resveratrol prevents interleukin-1β-induced dysfunction of pancreatic β-cells.

Chen F, Zhou X, Lin Y, Jing C, Yang T, Ji Y, Sun Y, Han X.

J Biomed Res. 2010 Sep;24(5):381-8. doi: 10.1016/S1674-8301(10)60051-6.


The lysine deacetylase inhibitor Givinostat inhibits β-cell IL-1β induced IL-1β transcription and processing.

Dahllöf MS, Christensen DP, Lundh M, Dinarello CA, Mascagni P, Grunnet LG, Mandrup-Poulsen T.

Islets. 2012 Nov-Dec;4(6):417-22. doi: 10.4161/isl.23541.


miR-296-3p, miR-298-5p and their downstream networks are causally involved in the higher resistance of mammalian pancreatic α cells to cytokine-induced apoptosis as compared to β cells.

Barbagallo D, Piro S, Condorelli AG, Mascali LG, Urbano F, Parrinello N, Monello A, Statello L, Ragusa M, Rabuazzo AM, Di Pietro C, Purrello F, Purrello M.

BMC Genomics. 2013 Jan 29;14:62. doi: 10.1186/1471-2164-14-62.

Items per page

Supplemental Content

Support Center